Improved In-Vitro Fertilisation (IVF) implantation success rate using advanced proteomic analysis of embryo culture fluid.

在英国，每七对夫妇中就有一对患有不孕症。子宫内膜异位症，多囊卵巢或排卵障碍影响20%的女性，而男性不育症则显着上升。世界卫生组织承认不孕症是一种疾病，它所造成的破坏和痛苦是众所周知的。英国国民保健制度为不孕夫妇提供有限的体外受精支持，但正在削减供应。私人诊所服务的需要，但与多个周期通常需要和25-30%的成功率，成本（£ 1，500- £ 5，000每个周期）和所涉及的压力是非常高的。胚胎质量不同，最好的最有可能植入并导致怀孕。胚胎学家使用培训和专业知识，使用物理标准和观察来选择胚胎，但这个过程既耗时又主观。胚胎镜和人工智能技术有可能改善结果，但每3-5天仅限于12个胚胎，并且仅提供视觉信息。市场强烈需要一种具有高通量和低成本的非侵入性预测技术，可以提高植入成功率，MAP Sciences开发了一种使用基质辅助激光解吸电离飞行时间质谱的诊断平台，MALDI-ToF（MALDI-ToF）和先进的蛋白质模式识别，使用人工智能，从临床样本中诊断疾病状态。MAP的研究表明，快速分析胚胎培养基与选择具有最高植入潜力的胚胎具有很强的相关性。MAP的突破性技术为最佳决策提供高质量、客观的代谢数据，从根本上提高植入成功率。该技术的主要特点是无创或组织破坏性，快速，高通量和负担得起。在英国获得专利。法国、德国、中国。MAP需要资源来扩大数据集和范围，通过与IVF诊所合作收集样本和数据，以在技术和商业上验证该技术，并通过IVDR - FDA验证创建最终产品。MAP已获得仪器制造商的承诺，以确保MAP软件的快速引入和强大支持。一个成功的项目结果在临床上、商业上以及从患者的角度、情感上和经济上都是重要的。

Infertility affects one in seven couples in the UK. Endometriosis, polycystic ovaries, or ovulation disorders affect 20% of women, while male infertility is rising significantly. The WHO recognises infertility as a disease, and the devastation and grief it causes is widely acknowledged.The NHS provides limited IVF support for infertile couples but is cutting provision. Private clinics service the need but with multiple cycles usually required and a 25-30% success rate, the costs (£1,500 - £5,000 per cycle) and stress involved are extremely high.Embryos vary in quality, the best most likely to implant and lead to a pregnancy. Embryologists use training and expertise to select embryos using physical criteria and observation but the process is time consuming and subjective. Embryoscope and AI technology potentially improves the outcome but is limited to 12 embryos per 3-5 day session and provides only visual information.There is a strong market need for a non-invasive, predictive technology, with high throughput and low cost, that can improve implantation success rate, and reduce the number of cycles.MAP Sciences has developed a diagnostic platform using Matrix Assisted Laser Desorption Ionisation Time of Flight Mass Spectrometry (MALDI-ToF) and advanced protein pattern recognition, using Artificial Intelligence, to diagnose disease states from clinical samples.MAP's research indicates strong correlation for rapid profiling of embryo culture media to select those embryos with highest implantation potential. MAP's ground-breaking technology provides high quality, objective metabolic data for optimal decision making, to radically improve implantation success rate. Key features of the technology are that is not invasive or tissue destructive, is rapid, high throughput, and affordable. Patents are granted in UK. France, Germany, China.Map requires resources to expand data sets and scope by collaborating with IVF clinics to collect samples and data to validate the technology both technically and commercially and create a final product with IVDR -- FDA validation.MAP has secured commitment from instrument manufacturers to ensure rapid introduction and robust support of MAP's software/reagent technology alongside existing and newly introduced machines.A successful project outcome is important clinically, commercially, and from the patient's perspective, emotionally and financially.